These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38488824)

  • 41. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
    Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
    Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic myeloid leukemia stem cells.
    Houshmand M; Simonetti G; Circosta P; Gaidano V; Cignetti A; Martinelli G; Saglio G; Gale RP
    Leukemia; 2019 Jul; 33(7):1543-1556. PubMed ID: 31127148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic myeloid leukemia stem cells.
    Kavalerchik E; Goff D; Jamieson CH
    J Clin Oncol; 2008 Jun; 26(17):2911-5. PubMed ID: 18539972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Cure of Chronic Myeloid Leukemia: Are We There Yet?
    Saikia T
    Curr Oncol Rep; 2018 Feb; 20(2):12. PubMed ID: 29492683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.
    Shah K; Parikh S; Rawal R
    Asian Pac J Cancer Prev; 2016; 17(7):3025-33. PubMed ID: 27509925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.
    Brumatti G; Kaloni D; Castro FA; Amarante-Mendes GP
    Biochem J; 2023 Jan; 480(2):161-176. PubMed ID: 36719792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells.
    Yahata T; Ibrahim AA; Hirano KI; Muguruma Y; Naka K; Hozumi K; Vaughan DE; Miyata T; Ando K
    Haematologica; 2021 Feb; 106(2):483-494. PubMed ID: 32001531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
    Agarwal P; Isringhausen S; Li H; Paterson AJ; He J; Gomariz Á; Nagasawa T; Nombela-Arrieta C; Bhatia R
    Cell Stem Cell; 2019 May; 24(5):769-784.e6. PubMed ID: 30905620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting survival pathways in chronic myeloid leukaemia stem cells.
    Sinclair A; Latif AL; Holyoake TL
    Br J Pharmacol; 2013 Aug; 169(8):1693-707. PubMed ID: 23517124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.
    Rothe K; Babaian A; Nakamichi N; Chen M; Chafe SC; Watanabe A; Forrest DL; Mager DL; Eaves CJ; Dedhar S; Jiang X
    Cell Stem Cell; 2020 Jul; 27(1):110-124.e9. PubMed ID: 32413332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
    Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
    J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
    Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
    Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
    Kuntz EM; Baquero P; Michie AM; Dunn K; Tardito S; Holyoake TL; Helgason GV; Gottlieb E
    Nat Med; 2017 Oct; 23(10):1234-1240. PubMed ID: 28920959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
    J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.